Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (4942)	11/26/2003 10:38:07 AM
From: DanZ	Read Replies (8) \| Respond to of 5582

That's very interesting. I wonder what happened to Viropharma's last partner? Even if Viropharma overcomes the problems that they have with Pleconaril, the drug will be sold as a prescription and won't be on the market until 2005, if they are lucky. VPHM is trading at 2.75, down 11 cents, so it doesn't appear that many people are buying the stock on the news. I guess they don't think that Viropharma will make much money on Pleconaril, or don't believe that the company will win FDA approval. If this were late 1999 - early 2000, the stock would have been hyped to 100 again on such news.